News
Two NIH Technology Transfer experts will be speaking at the Biotechnology Innovation Organization 2025 International Convention taking place in Boston, June 16-19, 2025, with pre-conference sessions taking place June 14-15. Steve Ferguson, Special Advisor at the NIH Office of Technology Transfer
Spravato ® is the first FDA approved prescription nasal spray for adults who suffer from treatment-resistant depression (TRD). Spravato was developed by Janssen Therapeutics from technology developed from a collaboration between the National Institute of Mental Health (NIMH), Yale University and
Traumatic Brain Injuries (TBI) are a major cause of death and disability. Current therapies to treat TBIs with neuroprotective agents are often limited by ability to achieve therapeutic concentrations of the therapeutic agent in the brain. Inventors at the National Institute of Neurological
Primary mediastinal B-cell lymphoma (PMBCL) is a non-Hodgkin lymphoma that accounts for 5-7% of all aggressive lymphomas. Diagnosing PMBCL can be challenging as the features overlap with diffuse large B-cell lymphoma (DLBCL), another type of non-Hodgkin lymphoma. These two lymphomas respond